Fluconazole resistance in Candida species: a current perspective

Fluconazole resistance in Candida species: a current perspective

Blog Article

Elizabeth L Berkow, Shawn R Lockhart Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract: Candida albicans and the emerging non-albicans Candida spp.have significant clinical relevance among many patient populations.Current Analysis on the imbalance of population flow network during the Spring Festival travel rush in China in 2015. treatment guidelines include fluconazole as a primary therapeutic option for the treatment of these infections, but it is only fungistatic against Candida spp.and both inherent and acquired resistance to fluconazole have been reported.Such mechanisms of resistance include increased drug efflux, alteration or increase in the drug target, and development of compensatory pathways for producing the target sterol, ergosterol.

While many mechanisms of resistance observed in C.albicans are also found in the non-albicans species, there are also important and unexpected differences between species.Furthermore, mechanisms of fluconazole resistance in emerging Candida spp., including the global health threat Managing Food Quality Risk in Global Supply Chain: A Risk Management Framework Candida auris, are largely unknown.In order to preserve the utility of one of our fundamental antifungal drugs, fluconazole, it is essential that we fully appreciate the manner by which Candida spp.

manifest resistance to it.Keywords: Candida, fluconazole resistance, ERG11, drug efflux, ergosterol.